Quadriceps tendon rupture associated with anabolic steroids and growth hormone: a case report

Abstract

Androgenic and human growth hormone derivatives have to potential to increase athletic performance despite increased risk of serious adverse effects. The risk of tendon rupture is very high in the anabolic androgenic steroid users. A 51-year-old male admitted to the emergency department with left knee pain following sport training. He had a history combination of androgenic hormones and insuline growth factor -1 use. Magnetic resonance imaging showed swelling, heterogeneity and partial discontinuity of the quadriceps tendon. Use of performance enhancing drugs has become a serious public health problem. Due to increase of abuse today it is possible to  encounter more side effects in the future and has to be considered as a growing public health problem. 

Keywords

• quadriceps tendon rupture,androgenic hormone,growth hormone

References

1. [1] Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006;38:644-51.
2. [2] Kanayama G, DeLuca J, Meehan WP 3rd, Hudson JI, Isaacs S, Baggish A, et al. Ruptured tendons in anabolic-androgenic steroid users: a cross-sectional cohort study. Am J Sports Med 2015;43:2638-44.
3. [3] Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014;24:383-98.
4. [4] United States Anti-Doping Agency - Results Management. http://www.usada.org/results/ (Accessed on January 11, 2011).
5. [5] Buckman JF, Farris SG, Yusko DA. A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances. Drug Alcohol Depend 2013;131:50-5.
6. [6] Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998;111:261-4.
7. [7] Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 2014;101:1271-9.
8. [8] Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014;35:341-75.

9. [9] King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999;281:2020-8.
10. [10] O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav 2002;75:557-66.
11. [11] Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172-81.
12. [12] Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend 2002;65:303-8.
13. [13] Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165-8.
14. [14] Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008;371:1872-82.
15. [15] Fernandez MM, Hosey RG. Performance-enhancing drugs snare nonathletes, too. J Fam Pract 2009;58:16-23.
16. [16] Segura J, Gutiérrez-Gallego R, Ventura R, Pascual JA, Bosch J, Such-Sanmartín G, et al. Growth hormone in sport: beyond Beijing 2008. Ther Drug Monit 2009;31:3-13.
17. [17] Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elbow Surg 1998;7:151-3.
18. [18] Cope MR, Ali A, Bayliss NC. Biceps rupture in body builders: three case reports of rupture of the long head of the biceps at the tendon-labrum junction. J Shoulder Elbow Surg 2004;13:580-2.